![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Preinitiation |
Unique ID issued by UMIN | UMIN000043386 |
Receipt No. | R000049527 |
Scientific Title | A Study on the Effect of Plant-Derived Product on Immune Function -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study- |
Date of disclosure of the study information | 2021/02/20 |
Last modified on | 2021/02/19 |
Basic information | ||
Public title | A Study on the Effect of Plant-Derived Product on Immune Function
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study- |
|
Acronym | A Study on the Effect of Plant-Derived Product on Immune Function | |
Scientific Title | A Study on the Effect of Plant-Derived Product on Immune Function
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study- |
|
Scientific Title:Acronym | A Study on the Effect of Plant-Derived Product on Immune Function | |
Region |
|
Condition | ||
Condition | No | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | To confirm the effect of plant-derived products on immune function. |
Basic objectives2 | Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | Salivary sIgA |
Key secondary outcomes | Skin moisture content
Physical condition questionnaire |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | Individual |
Blinding | Double blind -all involved are blinded |
Control | Placebo |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | Plant-Derived Products, 4 weeks consumption | |
Interventions/Control_2 | Placebo Products, 4 weeks consumption | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | (1)Healthy males and females aged 20 to 64 years-old.
(2)Subjects who can make self-judgment and are voluntarily giving written informed consent. |
|||
Key exclusion criteria | Subjects (who)
(1)have a faster salivary sIgA secretion rate. (2)have a constipation tendency. (3)contract diseases (e.g., diabetes, liver disease, kidney disease, heart disease, respiratory disease, endocrine disease and/or metabolic disease). (4)have a chronic disease and regularly use medications. (5)can't stop using supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting immune functions. (6)can't stop taking foods containing lactic acid bacteria, bifidobacteria, oligosaccharides, and/or live bacteria during test periods. (7)get intense exercises (e.g., muscle training in the gym) more than 3 times a week. (8)are under treatment for periodontal disease. (9)used antibiotics within the last two weeks prior to the screening. (10)can't stop drinking from a day before each measurement. (11)have declared an allergic reaction to test foods. (12)have a history and/or a surgical history of digestive disease affecting digestion and absorption. (13)plan to become pregnant after informed consent, pregnant or lactating. (14)are under treatment for or have a history of drug addiction and/or alcoholism. (15)are shiftworker and/or midnight-shift worker. (16)are participating and/or had participated and/or are planning to participate in other clinical studies that affect this study. (17)with skin disease, such as atopic dermatitis. (18)with strange skin conditions at measurement points. (19)neglect skin care. (20)can't avoid direct sunlight exposure, such as sunburn, during test periods. (21)had been conducted an operation or beauty treatment on the test spot in the past 6 months. (22)are judged unsuitable for the study by the investigator for other reasons. |
|||
Target sample size | 40 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | TOYO SHINYAKU Co., Ltd. | ||||||
Division name | Clinical and analytical research center | ||||||
Zip code | 841-0005 | ||||||
Address | 7-28 Yayoigaoka, Tosu-Shi, Saga, Japan | ||||||
TEL | 0942-81-3555 | ||||||
kadot@toyoshinyaku.co.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | TOYO SHINYAKU Co., Ltd. | ||||||
Division name | Clinical and analytical research center | ||||||
Zip code | 841-0005 | ||||||
Address | 7-28 Yayoigaoka, Tosu-Shi, Saga, Japan | ||||||
TEL | 0942-81-3555 | ||||||
Homepage URL | |||||||
gakujutsu@toyoshinyaku.co.jp |
Sponsor | |
Institute | TOYO SHINYAKU Co., Ltd. |
Institute | |
Department |
Funding Source | |
Organization | TOYO SHINYAKU Co., Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Miura Clinic, Medical Corporation Kanonkai IRB |
Address | 9F Higashitenma building, 1-7-17 Higashitenma, Kita-ku, Osaka, Osaka, Japan |
Tel | 06-6135-5200 |
mterashima@miura-cl.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Preinitiation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049527 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |